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Objectives: The aim of this study was to estimate cost/utility of infliximab for 
treatment of Chron’s disease in Serbia and to calculate impact on national health 
budget if it is used according to evidence-based guidance for treatment of inflamma-
tory bowel diseases. MethOds: Cost/utility of biological therapy of Chron’s disease 
(infliximab in the first line, adalimumab for the patients unresponsive to infliximab) 
vs. azathioprine was estimated by Markov model written in Excel 2007. The model 
has 9 health states, with 30 two-month cycles. The model was populated from the 
perspective of Serbian society, taking into account both direct and indirect costs 
expressed in Serbian dinars (1 Euro = 120 RSD). Both costs and quality-adjusted 
life years (QALYs) were discounted at uniform rate of 3%. The model outputs were 
generated by Monte Carlo microsimulation, and further used for budget impact 
analysis. Conclusions of the model were challenged by probabilistic sensitivity anal-
ysis. Results: Biological therapy was cost effective in comparison with standard 
therapy, with ICER value of 2,091,348.98 ± 1,156,213.78 RSD per QALY gained (99% 
CI), and Neto monetary benefit of 90,183.84 ± 135,055.30 RSD (99% CI). About 62% 
of virtual patients generated by the model simulation were below the willingness 
of pay of 3 GDP per capita per QALY gained. Price of infliximab was the most influ-
ential variable on Neto monetary benefit in the sensitivity analysis. If infliximab 
and adalimumab are 100% reimbursed by Serbian health insurance fund for 3,927 
patients with Chron’s disease in Serbia who need biological therapy, additional 
annual burden on health budget in Serbia would be 180,248,853.03 ± 333,531,117.81 
RSD (99% CI), or about 0.29% of total drug budget. cOnclusiOns: Biological therapy 
of Chron’s disease in Serbia is cost/effective option, which would impose moderate 
burden on national health budget after full implementation according to recom-
mendations of evidence-based international guidelines for treatment of inflam-
matory bowel diseases.
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Objectives: Calprotectin is a calcium binding protein released by neutrophils asso-
ciated with inflammation. A recent systematic review has confirmed the value of 
testing faecal calprotectin to help distinguish between organic (inflammatory bowel 
disease - IBD) and non-organic gastrointestinal disease (irritable bowel syndrome 
- IBS). National Institute of Clinical Excellence (NICE), UK guidelines were thus writ-
ten to guide general practitioners (GPs) in excluding IBD and to achieve savings by 
reducing the number of referrals to secondary care. We aimed to determine the 12 
month clinical outcomes of patients undergoing FC testing in primary and sec-
ondary care settings. MethOds: 495 FC test results between July 2012 to October 
2013 were reviewed. Paediatric patients (< 16 years old) were excluded. Patients not 
referred to secondary care/tertiary care had their GPs contacted for further details. 
Long term clinical data was available in 275 patients; 208 normal, 41 intermediate 
and 26 raised FC results. Results: 40% of patients with a normal FC result were 
still referred to secondary gastroenterology care, with only 26% managed in pri-
mary care. 12 months post FC testing revealed 9% of normal FC results remained 
in secondary care, compared to 34% for intermediate and 73% for raised results. A 
new diagnosis of IBD was made in 1% of patients with normal FC results, 19% of 
intermediate and 38% of raised FC results. Conversely a new diagnosis of IBS (non-
organic) was made in 40% of normal FC, 27% of intermediate and 7.7% of raised 
results. cOnclusiOns: Despite a normal FC, this study suggests that 40% are still 
being referred to secondary care for investigation. This suggests that the cost saving 
intended by NICE may have been overestimated. The proportion of normal FC results 
which are managed in primary care could be improved with better GP education 
and more stringent pathways.
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Objectives: The objective of this study is to determine the direct costs of the use 
of PPI for the treatment of erosive form (EF) and non-erosive form (NEF) of GERD 
in patients of working age in Ukraine. MethOds: Cost analysis for PPIs was con-
ducted for a minimum course of treatment of GERD in one patient: NEF – 4 weeks, 
EF – 8 weeks. Daily doses of preparations were used in calculations: omeprazole, 
rabeprazole - 20 mg; pantoprazole, esomeprazole - 40 mg; lansoprazole – 30 mg, 
(as recommended by the Ukrainian unified clinical protocol “Gastroesophageal 
Reflux Disease”, 2013). When calculating the direct costs, the cost of PPIs was only 
taken into account. Prices of drugs were taken from the Morion information system 
“Drugs” (November 2014). The rate of hryvnia to dollar (USD) as of 28.11.14 was 
14.96:1. To determine the range of costs for the use of PPIs, their trade names with 
the minimum and maximum costs of treatment of the disease in one patient were 
determined. Results: Ilaprazole achieved a better overall efficacy, because it is 
less impacted by CYP2C19 genotype subgroups. Compared with omeprazole, ilapra-
zole achieved an incremental cost effectiveness ratio of ¥132,056 per QALY gained 
which is less than the 3 times of China average GDP per capital (2014). A subgroup 
analysis suggests Ilaprazole is most cost-effective in the CYP2C19 subpopulation of 
Clinical efficacy and adverse event costs were not taken into consideration. The model 
also assumed reimbursement of infliximab-biosimilars in 2015 with low market-
penetration and conventional treatment almost steady throughout the three-year 
time horizon. Input data for estimated volumes were validated separately by two 
opinion leaders in gastroenterology (from a tertiary public and a private hospital), 
with vedolizumab experience through early-access programs. Any assumptions that 
showed discrepancies to expert opinion were converted to the average value of the 
two inputs. Values are in € 2015. Results: The increase in total costs from the intro-
duction of vedolizumab and biosimilars to the Greek healthcare system, would be 
€ 255,926, € 673,491 and € 814,924 for the three respective years post-entry (cumula-
tive € 1,744,341). Average incremental per patient cost for the first year was found to 
be € 249 when vedolizumab and biosimilars received 21% and 11% of total UC bio-
logic volumes respectively. Yearly total pharmaceutical UC expenditure ranged from 
€ 2,735,702 to € 3,016,905 in the absence of vedolizumab and € 2,991,628 to € 3,831,829 
when vedolizumab was available with estimated expenditure on biosimilar therapies 
not exceeding € 853,470 over three years. cOnclusiOns: Irrespective of the limita-
tions due to lack of country-specific data, vedolizumab introduction is not expected 
to exert significant pressure on third party pharmaceutical UC expenditure.
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Objectives: Crohn’s disease (CD) exerts significant burden to IBD-patients 
and payers. The aim of this study was to estimate the budget impact of ved-
olizumab in moderate/severe CD, from the perspective of the Greek healthcare 
setting. MethOds: A Microsoft Excel-based budget impact model was adapted 
for a hypothetical cohort of IBD patients with moderate/severe CD within the 
total Greek population. The budget impact was calculated and presented as incre-
mental drug-acquisition and administration costs, using input values obtained 
from National official databases, before and up to three years after the intro-
duction of vedolizumab versus standard of care. Clinical efficacy and adverse 
event costs were not taken into consideration. The model also assumed reim-
bursement of infliximab-biosimilars in 2015 with low market-penetration and 
conventional treatment almost steady throughout the three-year time horizon. 
Input data for estimated volumes of vedolizumab and biosimilars were validated 
separately by two opinion leaders in gastroenterology from a tertiary public and 
a private hospital, with vedolizumab experience through early-access programs. 
Any assumptions that showed discrepancies to expert opinion were converted to 
the average value of the two inputs. Values are in € 2015. Results: The increase 
in total costs from the introduction of vedolizumab and infliximab-biosimilars to 
the Greek healthcare system, would be € 195,600, € 519,429 and € 788,147 for the 
three respective years post-entry (cumulative € 1,503,176). Average incremental 
per patient cost for the first year was found to be € 164 when vedolizumab and 
biosimilars received 10.9% and 3.3% of total CD biologic volumes respectively. 
Yearly total pharmaceutical CD expenditure ranged from € 5,024,036 to € 5,653,930 
in the absence of vedolizumab and € 5,219,636 to € 6,442,077 when vedolizumab 
was available with estimated expenditure on biosimilar therapies not exceeding 
€ 745,000 over three years. cOnclusiOns: Irrespective of the limitations due to 
lack of country-specific data, vedolizumab introduction is not expected to exert 
significant pressure on third party pharmaceutical CD expenditure.
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Objectives: The new combination therapy of paritaprevir, ombitasvir, dasabu-
vir, with/without ribavirin is highly tolerable, all-oral, interferon-free regimen 
for treatment of chronic hepatitis C virus (HCV) infection. The objective of pre-
sent study was to evaluate the financial impact on the Croatian Health Insurance 
Fund (CHIF) budget following the introduction of the therapy for experienced 
HCV genotype 1 (GT1) patients. MethOds: The size of the eligible population 
for the new pharmaceutical combination was estimated by local demographics 
information, literature, and experts’ opinion. Only direct costs of pharmaceuti-
cals were taken into account. Budget impact calculations were based on health-
economic outcomes of the new therapy in comparison to alternative interventions 
(standard dual-therapy and triple therapies that include boceprevir, telaprevir and 
simeprevir) for different patient subpopulations. Patient subpopulations were dif-
ferentiated by response to previous treatment (relapse, partial response and null 
response), presence of cirrhosis and HCV GT1 subtype. Sensitivity analysis was 
performed in the form of alternative scenarios. Final parameters were estimated 
by Monte Carlo simulations. Results: The new combination therapy showed bet-
ter efficiency, shorter duration and better tolerance in comparison to alternative 
interventions. For certain patient subpopulations, the new therapy is cheaper per 
achieved SVR in comparison to other therapies. The estimated number of patients 
eligible for the new combination therapy is 90-100 per year and the expected 
annual value of increased expenditures for CIHF budget is in between approxi-
mately 200,000 – 900,000 € . cOnclusiOns: Although the impact on CHIF budget 
is significant, due to high efficiency and high tolerability, the new combination 
therapy for some patient subpopulations is cost-effective, that being the reason 
for its consideration as an alternative to standard therapies. Further, this economic 
evaluation could be the starting point for negotiations between pharmaceutical 
industry and insurance companies, as well as an introduction of specific contracts 
and some new technical solutions in those negotiations.
